Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

Expression of TNF-superfamily members BAFF and APRIL in breast cancer: Immunohistochemical study in 52 invasive ductal breast carcinomas

Authors: Vassiliki Pelekanou, Marilena Kampa, Maria Kafousi, Katerina Darivianaki, Elias Sanidas, Dimitrios D Tsiftsis, Efstathios N Stathopoulos, Andreas Tsapis, Elias Castanas

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

Recent studies suggest an association between chronic inflammation, modulating the tissue microenvironment, and tumor biology. Tumor environment consists of tumor, stromal and endothelial cells and infiltrating macrophages, T lymphocytes, and dendritic cells, producing an array of cytokines, chemokines and growth factors, accounting for a complex cell interaction and regulation of differentiation, activation, function and survival of tumor and surrounding cells, responsible for tumor progression and spreading or induction of antitumor immune responses and rejection. Tumor Necrosis Factor (TNF) family members (19 ligands and 29 receptors) represent a pleiotropic family of agents, related to a plethora of cellular events from proliferation and differentiation to apoptosis and tumor reduction. Among these members, BAFF and APRIL (CD257 and CD256 respectively) gained an increased interest, in view of their role in cell protection, differentiation and growth, in a number of lymphocyte, epithelial and mesenchymal structures.

Methods

We have assayed by immunohistochemistry 52 human breast cancer biopsies for the expression of BAFF and APRIL and correlated our findings with clinicopathological data and the evolution of the disease.

Results

BAFF was ubiquitely expressed in breast carcinoma cells, DCIS, normal-appearing glands and ducts and peritumoral adipocytes. In contrast, APRIL immunoreactive expression was higher in non-malignant as compared to malignant breast structures. APRIL but not BAFF immunoreactivity was higher in N+ tumors, and was inversely related with the grade of the tumors. Neither parameter was related to DFS or the OS of patients.

Conclusion

Our data show, for the first time, an autocrine secretion of BAFF and APRIL from breast cancer cells, offering new perspectives for their role in neoplastic and normal breast cell biology and offering new perspectives for possible selective intervention in breast cancer.
Appendix
Available only for authorised users
Literature
1.
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed
2.
3.
Balkwill F, Charles KA, Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005, 7: 211-217. 10.1016/j.ccr.2005.02.013.CrossRefPubMed
4.
Karin M, Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005, 5: 749-759. 10.1038/nri1703.CrossRefPubMed
5.
6.
Ben-Baruch A: Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol. 2006, 16: 38-52. 10.1016/j.semcancer.2005.07.006.CrossRefPubMed
7.
Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y: Cytokines in cancer immunity and immunotherapy. Immunol Rev. 2004, 202: 275-293. 10.1111/j.0105-2896.2004.00199.x.CrossRefPubMed
8.
Kim R, Emi M, Tanabe K, Arihiro K: Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006, 66: 5527-5536. 10.1158/0008-5472.CAN-05-4128.CrossRefPubMed
9.
Hadden JW: Immunodeficiency and cancer: prospects for correction. Int Immunopharmacol. 2003, 3: 1061-1071. 10.1016/S1567-5769(03)00060-2.CrossRefPubMed
10.
Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004, 431: 461-466. 10.1038/nature02924.CrossRefPubMed
11.
Karin M: Inflammation and cancer: the long reach of Ras. Nat Med. 2005, 11: 20-21. 10.1038/nm0105-20.CrossRefPubMed
12.
Bodmer JL, Schneider P, Tschopp J: The molecular architecture of the TNF superfamily. Trends Biochem Sci. 2002, 27: 19-26. 10.1016/S0968-0004(01)01995-8.CrossRefPubMed
13.
Hahne M, Kataoka T, Schroter M, Hofmann K, Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE, et al: APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. 1998, 188: 1185-1190. 10.1084/jem.188.6.1185.CrossRefPubMedPubMedCentral
14.
Kelly K, Manos E, Jensen G, Nadauld L, Jones DA: APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death. Cancer Res. 2000, 60: 1021-1027.PubMed
15.
Shu HB, Hu WH, Johnson H: TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol. 1999, 65: 680-683.PubMed
16.
Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, et al: TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000, 404: 995-999. 10.1038/35010115.CrossRefPubMed
17.
Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, et al: BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999, 189: 1747-1756. 10.1084/jem.189.11.1747.CrossRefPubMedPubMedCentral
18.
Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, et al: BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999, 285: 260-263. 10.1126/science.285.5425.260.CrossRefPubMed
19.
Gras MP, Laabi Y, Linares-Cruz G, Blondel MO, Rigaut JP, Brouet JC, Leca G, Haguenauer-Tsapis R, Tsapis A: BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes. Int Immunol. 1995, 7: 1093-1106. 10.1093/intimm/7.7.1093.CrossRefPubMed
20.
Dillon SR, Gross JA, Ansell SM, Novak AJ: An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov. 2006, 5: 235-246. 10.1038/nrd1982.CrossRefPubMed
21.
Hatzoglou A, Roussel J, Bourgeade MF, Rogier E, Madry C, Inoue J, Devergne O, Tsapis A: TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J Immunol. 2000, 165: 1322-1330.CrossRefPubMed
22.
Mackay F, Ambrose C: The TNF family members BAFF and APRIL: the growing complexity. Cytokine Growth Factor Rev. 2003, 14: 311-324. 10.1016/S1359-6101(03)00023-6.CrossRefPubMed
23.
Ng LG, Mackay CR, Mackay F: The BAFF/APRIL system: life beyond B lymphocytes. Mol Immunol. 2005, 42: 763-772. 10.1016/j.molimm.2004.06.041.CrossRefPubMed
24.
Kato A, Truong-Tran AQ, Scott AL, Matsumoto K, Schleimer RP: Airway epithelial cells produce B cell-activating factor of TNF family by an IFN-beta-dependent mechanism. J Immunol. 2006, 177: 7164-7172.CrossRefPubMedPubMedCentral
25.
Guan ZB, Dan WB, Shui Y, Ye JL, Zhang SQ: cDNA cloning, expression and bioactivity of porcine BAFF. Dev Comp Immunol. 2007, 31: 1211-1219. 10.1016/j.dci.2007.03.006.CrossRefPubMed
26.
Deshayes F, Lapree G, Portier A, Richard Y, Pencalet P, Mahieu-Caputo D, Horellou P, Tsapis A: Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor. Oncogene. 2004, 23: 3005-3012. 10.1038/sj.onc.1207350.CrossRefPubMed
27.
28.
Part VII, Breast. Cancer Staging Manual. Edited by Cancer AJCo. 2002, New York : Springer, 221-240.
29.
McCarty KS, Miller LS, Cox EB, Konrath J, McCarty KS: Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985, 109: 716-721.PubMed
30.
Lopez-Fraga M, Fernandez R, Albar JP, Hahne M: Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep. 2001, 2: 945-951. 10.1093/embo-reports/kve198.CrossRefPubMedPubMedCentral
31.
Molloy SS, Anderson ED, Jean F, Thomas G: Bi-cycling the furin pathway: from TGN localization to pathogen activation and embryogenesis. Trends Cell Biol. 1999, 9: 28-35. 10.1016/S0962-8924(98)01382-8.CrossRefPubMed
32.
Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I, Browning JL: TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem. 1997, 272: 32401-32410. 10.1074/jbc.272.51.32401.CrossRefPubMed
33.
Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, Migone TS, Sosnovtseva S, Carrell JA, Feng P, Giri JG, Hilbert DM: Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood. 2001, 97: 198-204. 10.1182/blood.V97.1.198.CrossRefPubMed
34.
Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H: Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med. 2000, 192: 1373-1380. 10.1084/jem.192.9.1373.CrossRefPubMedPubMedCentral
35.
Bossen C, Schneider P: BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol. 2006, 18: 263-275. 10.1016/j.smim.2006.04.006.CrossRefPubMed
36.
Dempsey PW, Doyle SE, He JQ, Cheng G: The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev. 2003, 14: 193-209. 10.1016/S1359-6101(03)00021-2.CrossRefPubMed
37.
Hendriks J, Planelles L, de Jong-Odding J, Hardenberg G, Pals ST, Hahne M, Spaargaren M, Medema JP: Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ. 2005, 12: 637-648. 10.1038/sj.cdd.4401647.CrossRefPubMed
38.
39.
40.
Perrimon N, Bernfield M: Specificities of heparan sulphate proteoglycans in developmental processes. Nature. 2000, 404: 725-728. 10.1038/35008000.CrossRefPubMed
41.
Ingold K, Zumsteg A, Tardivel A, Huard B, Steiner QG, Cachero TG, Qiang F, Gorelik L, Kalled SL, Acha-Orbea H, et al: Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med. 2005, 201: 1375-1383. 10.1084/jem.20042309.CrossRefPubMedPubMedCentral
42.
Sakurai D, Hase H, Kanno Y, Kojima H, Okumura K, Kobata T: TACI regulates IgA production by APRIL in collaboration with HSPG. Blood. 2007, 109: 2961-2967.PubMed
43.
Bischof D, Elsawa SF, Mantchev G, Yoon J, Michels GE, Nilson A, Sutor SL, Platt JL, Ansell SM, von Bulow G, Bram RJ: Selective activation of TACI by syndecan-2. Blood. 2006, 107: 3235-3242. 10.1182/blood-2005-01-0256.CrossRefPubMedPubMedCentral
44.
Mhawech-Fauceglia P, Kaya G, Sauter G, McKee T, Donze O, Schwaller J, Huard B: The source of APRIL up-regulation in human solid tumor lesions. J Leukoc Biol. 2006, 80: 697-704. 10.1189/jlb.1105655.CrossRefPubMed
45.
Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M: Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999, 68: 729-777. 10.1146/annurev.biochem.68.1.729.CrossRefPubMed
46.
Chiu A, Xu W, He B, Dillon SR, Gross JA, Sievers E, Qiao X, Santini P, Hyjek E, Lee JW, et al: Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood. 2007, 109: 729-739. 10.1182/blood-2006-04-015958.CrossRefPubMedPubMedCentral
47.
Schaffler A, Scholmerich J, Salzberger B: Adipose tissue as an immunological organ: Toll-like receptors, C1q/TNFs and CTRPs. Trends Immunol. 2007
48.
Cawthorn WP, Heyd F, Hegyi K, Sethi JK: Tumour necrosis factor-alpha inhibits adipogenesis via a beta-catenin/TCF4(TCF7L2)-dependent pathway. Cell Death Differ. 2007
49.
Nelson-Dooley C, Della-Fera MA, Hamrick M, Baile CA: Novel treatments for obesity and osteoporosis: targeting apoptotic pathways in adipocytes. Curr Med Chem. 2005, 12: 2215-2225. 10.2174/0929867054864886.CrossRefPubMed
Metadata
Title
Expression of TNF-superfamily members BAFF and APRIL in breast cancer: Immunohistochemical study in 52 invasive ductal breast carcinomas
Authors
Vassiliki Pelekanou
Marilena Kampa
Maria Kafousi
Katerina Darivianaki
Elias Sanidas
Dimitrios D Tsiftsis
Efstathios N Stathopoulos
Andreas Tsapis
Elias Castanas
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-76

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Retinoic acid reduces human neuroblastoma cell migration and invasiveness: effects on DCX, LIS1, neurofilaments-68 and vimentin expression

Research article

Antioxidant intervention of smoking-induced lung tumor in mice by vitamin E and quercetin

Research article

Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison

Research article

Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent

Research article

Cancer Trajectories at the End of Life: is there an effect of age and gender?

Research article

Prodrug converting enzyme gene delivery by L. monocytogenes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits